162 related articles for article (PubMed ID: 38658742)
21. Imeglimin preserves islet β-cell mass in Type 2 diabetic ZDF rats.
Hallakou-Bozec S; Kergoat M; Moller DE; Bolze S
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00193. PubMed ID: 33855202
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 (DPP-4) inhibitors.
Patel BD; Bhadada SV; Ghate MD
Bioorg Chem; 2017 Jun; 72():345-358. PubMed ID: 28302310
[TBL] [Abstract][Full Text] [Related]
23. Antidiabetic effects of flavonoids from Sophora flavescens EtOAc extract in type 2 diabetic KK-ay mice.
Yang X; Yang J; Xu C; Huang M; Zhou Q; Lv J; Ma X; Ke C; Ye Y; Shu G; Zhao P
J Ethnopharmacol; 2015 Aug; 171():161-70. PubMed ID: 26051831
[TBL] [Abstract][Full Text] [Related]
24. Antidiabetic Activity of Dihydropyrimidine Scaffolds and Structural Insight by Single Crystal X-ray Studies.
Bairagi KM; Younis NS; Emeka PM; Sangtani E; Gonnade RG; Venugopala KN; Alwassil OI; Khalil HE; Nayak SK
Med Chem; 2020; 16(7):996-1003. PubMed ID: 31880253
[TBL] [Abstract][Full Text] [Related]
25. The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, in alloxan- and streptozocin-induced diabetic rats.
Liu Z; Li J; Zeng Z; Liu M; Wang M
Chem Biol Interact; 2008 May; 173(1):68-75. PubMed ID: 18377884
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, Characterisation, Molecular Docking, Anti-microbial and Anti-diabetic Screening of Substituted 4-indolylphenyl-6-arylpyrimidine-2-imine Derivatives.
Ramya V; Vembu S; Ariharasivakumar G; Gopalakrishnan M
Drug Res (Stuttg); 2017 Sep; 67(9):515-526. PubMed ID: 28628926
[TBL] [Abstract][Full Text] [Related]
27. New Biguanides as Anti-Diabetic Agents Part I: Synthesis and Evaluation of 1-Substituted Biguanide Derivatives as Anti-Diabetic Agents of Type II Diabetes Insulin Resistant.
Abbas SY; Basyouni WM; El-Bayouk KAM; Tohamy WM; Aly HF; Arafa A; Soliman MS
Drug Res (Stuttg); 2017 Oct; 67(10):557-563. PubMed ID: 28651259
[TBL] [Abstract][Full Text] [Related]
28. Metformin and Bee Venom: a Comparative Detection of Histological Alteration of the Pancreas and Systemic Inflammatory Markers in Diabetic Mice.
Al-Sarray RAH; Al-Shaeli SJJ
Arch Razi Inst; 2022 Dec; 77(6):2335-2343. PubMed ID: 37274913
[TBL] [Abstract][Full Text] [Related]
29. Development of a Novel Zebrafish Model for Type 2 Diabetes Mellitus.
Zang L; Shimada Y; Nishimura N
Sci Rep; 2017 May; 7(1):1461. PubMed ID: 28469250
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, molecular docking and anti-diabetic evaluation of 2,4-thiazolidinedione based amide derivatives.
Naim MJ; Alam MJ; Nawaz F; Naidu VGM; Aaghaz S; Sahu M; Siddiqui N; Alam O
Bioorg Chem; 2017 Aug; 73():24-36. PubMed ID: 28582649
[TBL] [Abstract][Full Text] [Related]
31. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
[TBL] [Abstract][Full Text] [Related]
32. Antidiabetic compounds 8a, 8b, 8k, and 9h enhance insulin secretion: activity and mechanism.
Li H; Zhang J; Fu Y; Zhang Y; Zhang C; Sun X; Wu F; He J
Endocrine; 2021 Feb; 71(2):365-377. PubMed ID: 33219494
[TBL] [Abstract][Full Text] [Related]
33. Antidiabetic effect of total flavonoids from Sanguis draxonis in type 2 diabetic rats.
Chen F; Xiong H; Wang J; Ding X; Shu G; Mei Z
J Ethnopharmacol; 2013 Oct; 149(3):729-36. PubMed ID: 23933499
[TBL] [Abstract][Full Text] [Related]
34. Metformin inhibits MAPK signaling and rescues pancreatic aquaporin 7 expression to induce insulin secretion in type 2 diabetes mellitus.
He X; Gao F; Hou J; Li T; Tan J; Wang C; Liu X; Wang M; Liu H; Chen Y; Yu Z; Yang M
J Biol Chem; 2021 Aug; 297(2):101002. PubMed ID: 34303707
[TBL] [Abstract][Full Text] [Related]
35. Preservation effect of imeglimin on pancreatic β-cell mass: Noninvasive evaluation using
Fauzi M; Murakami T; Fujimoto H; Botagarova A; Sakaki K; Kiyobayashi S; Ogura M; Inagaki N
Front Endocrinol (Lausanne); 2022; 13():1010825. PubMed ID: 36246910
[TBL] [Abstract][Full Text] [Related]
36. A preclinical overview of metformin for the treatment of type 2 diabetes.
Zhou T; Xu X; Du M; Zhao T; Wang J
Biomed Pharmacother; 2018 Oct; 106():1227-1235. PubMed ID: 30119191
[TBL] [Abstract][Full Text] [Related]
37. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
[TBL] [Abstract][Full Text] [Related]
38. Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents.
Perry RJ; Cardone RL; Petersen MC; Zhang D; Fouqueray P; Hallakou-Bozec S; Bolze S; Shulman GI; Petersen KF; Kibbey RG
Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E461-70. PubMed ID: 27406738
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, nitric oxide release, and dipeptidyl peptidase-4 inhibition of sitagliptin derivatives as new multifunctional antidiabetic agents.
Xie Y; Shao L; Wang Q; Bai Y; Chen Z; Li N; Xu Y; Li Y; Yang G; Bian X
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3731-3735. PubMed ID: 30343953
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
